Mesalazine Modified-Release Tablet in the Treatment of Ulcerative Colitis in the Remission Phase: A Chinese, Multicenter, Single-Blind, Randomized Controlled Study

Conclusion Mesalazine modified-release tablets were non-inferior to the enteric-coated tablets and may be considered an effective and safe treatment alternative for the maintenance of remission in Chinese patients with UC. Trial registration ClinicalTrials.gov identifier: NCT01257399. Funding Tillotts Pharma AG.

http://link.springer.com/10.1007/s12325-016-0304-y

Source: Advances in Therapy - February 23, 2016 Category: Drugs & Pharmacology Source Type: research